The Motley Fool

How to make a million WITHOUT buying ‘sin stocks’

With the festive season well under way, I thought it would be a good time to contemplate whether it is possible to build a winning investment portfolio based on sound ethical principles. But then I hit my first obstacle. What does ‘ethical’ mean?

Does your mother know

Ask 10 people what ethical means and you’ll probably get 10 different answers, and kick off a heated discussion about the topic. It can be a rather emotive subject for investors too. Some would be quite happy to include oil and mining stocks in an ethical portfolio, yet others would cite their negative environmental impact and say they were therefore unethical.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

So finally I decided to narrow the scope to so-called ‘sin stocks’. It’s generally accepted that ‘sin stocks’ are those belonging to sectors that include alcohol, tobacco, gambling, weapons manufacture, and other naughty things you wouldn’t want your mother to know about.


It’s not as easy as it seems, when you consider that companies in these sectors have generally outperformed the market over the years, with many now even considered as ‘defensives’. In other words, even when the economy is struggling, people are less likely to cut back on booze and tobacco for instance, than they are on retail and housing.

What does it say about society when alcohol, tobacco, and gambling rank alongside gas, water, electricity, toothpaste, and toilet paper as everyday essentials? When times are good – people drink, smoke and gamble. When times aren’t so good, they do so even more.

A healthier alternative

Core holdings like Diageo, Imperial Brands and British American Tobacco might not be that well known to those outside the investment community. But with instantly-recognisable global brands such Guinness, Baileys, Rothmans and Lucky Strike in their portfolios, these three goliaths last year managed to amass sales in excess of £60bn, with a large chunk of the profits being distributed to their shareholders.

Is there an alternative? I think there is. Why not invest in equally defensive companies that produce inhalers, vaccines, and cancer treatments? I’m talking about London-listed pharmaceutical giants GlaxoSmithKline and AstraZeneca. Both are go-to stocks in times of economic uncertainty, and both pay healthy dividends to their loyal shareholders. You’ll probably feel better about it too.

The only way is ethics

As one of the world’s largest weapons suppliers, BAE Systems has long been a target for both campaigners and investors, with the multinational defence contractor last year pulling in almost £19bn of business from countries all around the world.

Medical technology business Smith & Nephew on the other hand has been helping the wounded since the outbreak of the First World War. The company’s advanced wound management and joint replacement systems have helped to deliver an enviable track record of revenue and earnings growth over the years, and I see the company as a worthy alternative to BAE in a ‘sinless’ portfolio.

And as more corporations realise their customers expect them to ‘do good’ (as well as making good products) they’re more likely to take an actively ethical approach to business, making it even easier to avoid sin stocks.

As you can see, it’s just as easy to build a winning portfolio with companies you’d be proud to own, as it is with more ethically-challenged stocks. So why not give it a try?

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to read our presentation.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca, Diageo, and Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.